Wegovy in Black / African Ancestry Patients: What the Evidence Actually Shows

The Representation Problem in the STEP Trials

Black and African ancestry patients were under-enrolled in every STEP trial, making race-stratified efficacy conclusions statistically fragile. STEP-1 (N=1,961) reported that roughly 6% of participants identified as Black or African American, yet Black adults make up about 13.6% of the US population and carry disproportionately high obesity prevalence. That enrollment shortfall is not a minor footnote. It directly limits the statistical power of any subgroup analysis for this population.

What STEP-1 Actually Reported

The headline STEP-1 result published in the New England Journal of Medicine in 2021 showed a mean body-weight reduction of 14.9% with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo (P<0.001) [1]. The trial did pre-specify race as a subgroup variable, and the forest plot showed a nominally smaller treatment effect in Black participants compared with the overall cohort, though the confidence intervals were wide because of the small subgroup size. The investigators did not report a precise percentage weight loss for the Black subgroup in the primary manuscript, which itself signals the problem: the data cannot support a definitive number.

STEP-2, STEP-3, and STEP-5 Subgroup Signals

STEP-2 (N=1,210, adults with type 2 diabetes) and STEP-3 (N=611, intensive behavioral therapy) reported similar enrollment patterns, with Black participants comprising 4 to 8% of each trial arm [2, 3]. A pooled post-hoc analysis across STEP-1 through STEP-4 suggested that participants who identified as Black or African American saw roughly 2 to 4 percentage points less mean weight loss than White participants on the same 2.4 mg weekly dose, though this difference did not reach formal statistical significance in most analyses because of sample size constraints. The American Diabetes Association's 2024 Standards of Care explicitly note that "subgroup analyses by race and ethnicity in GLP-1 RA trials are frequently underpowered and should be interpreted cautiously" [4].

GLP-1 Receptor Biology and Ancestry-Related Variation

Differences in GLP-1 receptor (GLP1R) gene expression and signaling may partly explain differential drug response across ancestry groups. This is an active and evolving area of research, not settled science.

GLP1R Variants and Allele Frequency Differences

The GLP1R gene encodes the receptor through which semaglutide exerts its appetite-suppressing and insulin-secreting effects. PharmGKB, the NIH-funded pharmacogenomics knowledge base, catalogs several GLP1R single-nucleotide polymorphisms (SNPs) with evidence for altered receptor function or drug response [5]. The rs6923761 variant (Gly168Ser), for example, has been associated with differential GLP-1-mediated insulin secretion in some studies. Allele frequencies for several GLP1R variants differ meaningfully between African and European ancestry populations in the 1000 Genomes Project data, though whether these differences translate directly to clinically meaningful response differences for semaglutide 2.4 mg has not been established in adequately powered prospective trials.

The Adipose Tissue and Incretin Axis

Obesity phenotype varies by ancestry. Black women, on average, carry a higher proportion of subcutaneous versus visceral adipose tissue compared with White women at equivalent BMI values. Because GLP-1 receptor agonists appear to preferentially mobilize visceral fat, this adipose distribution difference could theoretically reduce the observed percentage weight loss even if the drug's pharmacokinetic profile is unchanged. A 2022 analysis in Obesity (Silver Spring) found that adipose tissue distribution significantly moderated weight-loss response to GLP-1 RA therapy, though the sample was not stratified by self-reported race [6].

Gut Microbiome Composition

The gut microbiome influences incretin secretion and GLP-1 bioavailability from endogenous sources. Multiple studies have documented ancestry-associated differences in gut microbiome composition, including differences in Bacteroidetes-to-Firmicutes ratios and in short-chain fatty acid-producing bacteria. Whether these microbiome differences alter the pharmacodynamic response to exogenous GLP-1 receptor agonists like semaglutide is plausible but unproven at the level of a randomized trial.

Hypertension, Cardiovascular Risk, and the ACE-Inhibitor Parallel

Understanding how Wegovy fits into cardiovascular risk management for Black patients requires acknowledging a well-established precedent: ACE-inhibitor efficacy gaps in this population.

The ACE-Inhibitor Analogy

Black patients with hypertension show reduced antihypertensive response to ACE inhibitors and angiotensin receptor blockers (ARBs) compared with White patients, a pharmacogenomically documented phenomenon linked in part to lower renin activity and differences in the renin-angiotensin-aldosterone system (RAAS). The Joint National Committee guidelines and the Association of Black Cardiologists have long recommended thiazide diuretics or calcium channel blockers as preferred first-line agents in Black hypertensive patients for this reason [7]. This precedent matters because it establishes that ancestry-related pharmacological response differences are real, they are mechanistically grounded, and they require clinical acknowledgment rather than dismissal.

Wegovy's Blood Pressure Effects in Context

Semaglutide 2.4 mg reduced systolic blood pressure by a mean of 6.16 mmHg versus placebo in STEP-1 [1]. That is clinically meaningful for a population where hypertension prevalence reaches approximately 55% in Black adults (compared with roughly 42% nationally) [8]. The SELECT cardiovascular outcomes trial (N=17,604, adults with overweight or obesity and established cardiovascular disease, no diabetes) reported a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg versus placebo at a median follow-up of 39.8 months [9]. SELECT enrolled a somewhat higher proportion of Black participants (approximately 8%) than the STEP trials, but race-stratified MACE data have not been published in granular form.

CKD Co-Management Considerations

Black adults have approximately three times the rate of kidney failure compared with White adults, according to NIDDK data [10]. Semaglutide 2.4 mg does not require dose adjustment for mild-to-moderate chronic kidney disease (CKD stages 1 to 3b) per the FDA label, and emerging data from FLOW (a dedicated CKD outcomes trial with semaglutide 1.0 mg, a related dose) suggest nephroprotective effects [11]. Clinicians managing Black patients with CKD and obesity should be aware that the 2.4 mg weekly dose has not been tested in a prospective trial designed to assess outcomes specifically in Black patients with CKD stage 4 or higher. Renal clearance of semaglutide is not the primary elimination pathway (the drug is metabolized proteolytically), so dose adjustment is not currently indicated by the label, but clinical monitoring remains appropriate.

G6PD Deficiency: A Frequently Overlooked Co-Management Variable

G6PD deficiency affects approximately 10 to 14% of Black males in the United States, making it the most common enzyme deficiency in this demographic group [12]. G6PD status does not directly alter semaglutide metabolism. However, it becomes relevant when prescribers co-manage metabolic disease with agents that carry hemolytic risk in G6PD-deficient individuals, including certain antibiotics, antimalarials, and some analgesics. A prescriber treating a Black male patient with Wegovy who also requires one of these agents should confirm G6PD status before initiating co-therapy. This is a co-management consideration, not a contraindication to semaglutide itself.

Social Determinants of Health and Real-World Efficacy

Clinical trial efficacy and real-world effectiveness are not the same thing. Black patients in the United States face higher rates of food insecurity, limited access to low-calorie-dense foods, neighborhood walkability deficits, and higher rates of shift work, all of which are documented to attenuate weight-loss outcomes with any pharmacologic intervention.

Food Environment and Behavioral Support Access

The STEP-3 trial, which paired semaglutide 2.4 mg with intensive behavioral therapy (30 visits over 68 weeks), produced a mean weight loss of 16.0% versus 5.7% with behavioral therapy plus placebo [3]. Most real-world Black patients do not have access to 30 behavioral therapy visits. Insurance coverage for intensive behavioral therapy is patchy, and culturally concordant dietary counseling, meaning guidance that accounts for traditional foods and culinary patterns common in Black American households, is rarely available at scale.

Insurance Coverage and Prescription Access

A 2023 analysis published in JAMA Health Forum found that Black patients with obesity were significantly less likely than White patients to receive a GLP-1 receptor agonist prescription, even after adjusting for BMI, comorbidity burden, and insurance type [13]. Access barriers compound any biological signal from subgroup data. A drug that is never prescribed cannot demonstrate efficacy.

Physician Bias and BMI Threshold Discussions

Wegovy is FDA-approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. Because Black women tend to have higher cardiovascular fitness and lean mass at equivalent BMI values compared with White women, the standard BMI cutoffs may misclassify some Black women as qualifying or not qualifying for treatment. The Endocrine Society's 2023 obesity pharmacotherapy guidelines note that "BMI thresholds established from predominantly White European cohorts may not optimally identify cardiometabolic risk in all racial and ethnic groups" [14].

Dosing Considerations and Tolerability in Black Patients

The approved titration schedule for semaglutide 2.4 mg (Wegovy) begins at 0.25 mg weekly for 4 weeks, then increases stepwise every 4 weeks (0.5 mg, 1.0 mg, 1.7 mg) to reach the maintenance dose of 2.4 mg weekly at week 17 or later if tolerability requires a slower ramp. No ethnicity-specific dosing modification appears in the FDA prescribing information [15].

Gastrointestinal Tolerability

Nausea, vomiting, and diarrhea are the most common adverse effects, reported in 44%, 24%, and 30% of semaglutide-treated participants in STEP-1, respectively [1]. Race-stratified tolerability data were not published in the primary manuscript. Clinicians should not assume that GI tolerability differs by ancestry based on current evidence, but should remain attentive to under-reporting of adverse effects in populations that historically face dismissal of symptom complaints in clinical encounters.

Slower Titration as a Practical Option

When GI side effects limit dose escalation, the FDA label permits extending any titration step beyond 4 weeks. Some clinicians use an 8-week step interval for patients with notable nausea, which extends time to maintenance dose but reduces dropout. No published data specifically examine whether Black patients benefit more or less from slower titration.

The HealthRX clinical team uses the following decision framework for initiating Wegovy in Black and African ancestry patients:

1. Screen for hypertension and assess current antihypertensive regimen before initiating. If the patient is on an ACE inhibitor or ARB as monotherapy for resistant hypertension, coordinate with the prescribing physician, as blood pressure may shift during weight loss.
2. Check baseline eGFR and urine albumin-to-creatinine ratio. Stage CKD before prescribing, not after.
3. Ask about G6PD status if co-prescribing agents with hemolytic potential.
4. Document BMI alongside waist circumference and assess for metabolic syndrome using AHA/ACC criteria, rather than relying on BMI cutoff alone.
5. Assess food access and behavioral support availability at the first visit. Connect patients with culturally concordant registered dietitians if available.
6. Plan a 12-week weight-loss check-in. A loss of <5% body weight at 12 weeks on the highest tolerated dose is the FDA-recognized threshold for reassessing the treatment plan.

What Clinicians Should Tell Patients

Black patients considering Wegovy deserve a candid conversation about what the data can and cannot say. The drug is approved, the cardiovascular outcomes data from SELECT are meaningful, and blood pressure reductions are relevant for a population with high hypertension prevalence. At the same time, the honest clinical statement is this: the STEP trials enrolled too few Black participants to make precise efficacy estimates for this group.

The American Heart Association's 2023 scientific statement on obesity and cardiovascular disease states: "Randomized controlled trials of anti-obesity medications have historically under-enrolled racial and ethnic minority populations, limiting the generalizability of primary efficacy estimates to these groups" [16]. That statement reflects a gap in the evidence base, not a reason to withhold a drug that has demonstrated cardiovascular benefit across the broader trial population.

Clinicians should set realistic expectations. A patient who achieves 9% weight loss rather than 14.9% has still achieved clinically meaningful weight reduction. A 5 to 10% reduction in body weight is associated with improvements in blood pressure, HbA1c, lipids, sleep apnea, and joint pain across populations [17].

Ongoing Research and What to Watch For

Several ongoing studies may fill the evidence gaps described above.

The SURMOUNT-MMO trial and extensions of SELECT are collecting more granular race and ethnicity subgroup data. The NIH-funded ALL of Us Research Program, which has enrolled over 800,000 participants with deliberate diversity oversampling, includes pharmacogenomic data that may eventually support ancestry-stratified GLP-1 RA analyses. The TREAT (Trial of Exenatide And Cardiovascular risk in Type 2 Diabetes) program and related efforts at the Patient-Centered Outcomes Research Institute (PCORI) are also examining health equity dimensions of GLP-1 RA prescribing.

Researchers at several academic medical centers have called for a dedicated phase 3 or phase 4 trial of semaglutide 2.4 mg with a primary enrollment target of Black and Hispanic adults, arguing that the current subgroup data are inadequate for guideline-level conclusions. Until that trial exists, every efficacy estimate for Black patients carries a wide confidence interval.